Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Amiloride. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCNN1A known ✓ | P37088 | 11/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.54 |
| ▸ | HPGD | P15428 | 7/20 | 0.54 |
| ▸ | GLA | P06280 | 7/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.54 |
| ▸ | PLAU | P00749 | 2/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | GMNN | O75496 | 3/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.52 |
| ▸ | BLM | P54132 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.51 |
| ▸ | GAA | P10253 | 4/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amiloride SCHEMBL317394 | 1.00 | SCNN1A (0.56) | SCNN1AALDH1A1KDM4EHPGDGLA | |
| Amiloride SCHEMBL29129215 | 0.98 | SCNN1A (0.57) | SCNN1AALDH1A1KDM4EHPGDGLA | |
| Amiloride SCHEMBL41233 | 0.98 | SCNN1A (0.57) | SCNN1AALDH1A1KDM4EHPGDGLA | |
| Amiloride SCHEMBL15517241 | 0.97 | SCNN1A (0.58) | SCNN1AALDH1A1KDM4EHPGDGLA | |
| Amiloride SCHEMBL27562 | 0.97 | SCNN1A (0.58) | SCNN1AALDH1A1KDM4EHPGDGLA | |
| Amiloride SCHEMBL41234 | 0.95 | SCNN1A (0.55) | SCNN1AALDH1A1KDM4EHPGDGLA | |
| Amiloride SCHEMBL1441814 | 0.95 | SCNN1A (0.57) | SCNN1AALDH1A1KDM4EHPGDGLA | |
| Amiloride SCHEMBL17986365 | 0.95 | SCNN1A (0.57) | SCNN1AALDH1A1KDM4EHPGDGLA | |
| Amiloride SCHEMBL21524891 | 0.95 | SCNN1A (0.57) | SCNN1AALDH1A1KDM4EHPGDGLA | |
| Amiloride SCHEMBL3253482 | 0.95 | SCNN1A (0.57) | SCNN1AALDH1A1KDM4EHPGDGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12004506-B2 | Pharmaceutical composition comprising a cyclic peptide of formula X1-GQRETPEGAEAKPWY-X2 and use for extracorporeal lung treatment | APEPTICO FORSCHUNG UND ENTWICKLUNG GMBH (AT) | 2024-06-11 | — | — | US | disclosed |
| US-11773445-B1 | Diagnostic methods | GRIFFITH UNIVERSITY | 2023-10-03 | — | — | US | disclosed |
| CN-115887410-A | Nano degradation agent for wide-spectrum degradation of cytoplasmic protein and preparation and application thereof | 北京大学 | 2023-04-04 | — | — | CN | disclosed |
| US-10946096-B2 | Nitrobenzaldehyde proton release for manipulation of cellular acidosis | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-03-16 | — | — | US | disclosed |
| US-20210069180-A1 | METHODS FOR TREATING CHRONIC FATIGUE SYNDROME AND MYALGIC ENCEPHALOMYELITIS | GRIFFITH UNIVERSITY (AU) | 2021-03-11 | — | — | US | disclosed |
| US-20200352156-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A CYCLIC PEPTIDE OF FORMULA X1-GQRETPEGAEAKPWY-X2 AND USE FOR EXTRACORPOREAL LUNG TREATMENT | APEPTICO FORSCHUNG UND ENTWICKLUNG GMBH (AT) | 2020-11-12 | — | — | US | disclosed |
| EP-3110448-B1 | NITROBENZALDEHYDE PROTON RELEASE FOR MANIPULATION OF CELLULAR ACIDOSIS | UNIV TEXAS (US) | 2020-09-09 | — | — | EP | disclosed |
| EP-2988769-B1 | EXTRACORPOREAL LUNG TREATMENT WITH A CYCLIC PEPTIDE OF FORMULA X1-GQRETPEGAEAKPWY-X2 | APEPTICO FORSCHUNG & ENTWICKLUNG GMBH (AT) | 2020-05-27 | — | — | EP | disclosed |
| EP-3289106-A1 | DIAGNOSTIC METHODS | Griffith University (AU) | 2018-03-07 | — | — | EP | disclosed |
| US-20170202964-A1 | NITROBENZALDEHYDE PROTON RELEASE FOR MANIPULATION OF CELLULAR ACIDOSIS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2017-07-20 | — | — | US | disclosed |
| EP-2988769-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A CYCLIC PEPTIDE OF FORMULA X1 -GQRETPEGAEAKPWY-X2 AND USE FOR EXTRACORPOREAL LUNG TREATMENT | APEPTICO Forschung und Entwicklung GmbH (AT) | 2016-03-02 | — | — | EP | disclosed |
| WO-2015130997-A1 | NITROBENZALDEHYDE PROTON RELEASE FOR MANIPULATION OF CELLULAR ACIDOSIS | GDOVIN MATTHEW (US) | 2015-09-03 | — | — | WO | disclosed |
| WO-2014194931-A1 | PATHOGEN REDUCTION TREATMENT | ONDERZOEKS- EN ONTWIKKELINGSFONDS RODE KRUIS-VLAANDEREN (BE) | 2014-12-11 | — | — | WO | disclosed |
| WO-2014173843-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A CYCLIC PEPTIDE OF FORMULA X1 -GQRETPEGAEAKPWY-X2 AND USE FOR EXTRACORPOREAL LUNG TREATMENT | APEPTICO FORSCHUNG UND ENTWICKLUNG GMBH (AT) | 2014-10-30 | — | — | WO | disclosed |
| US-20120148604-A1 | TRP INHIBITORS AND USES THEREOF | TRANSPOSAGEN BIOPHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20110077212-A1 | THERAPEUTIC USES OF SGLT2 INHIBITORS | THERACOS, INC. (US) | 2011-03-31 | — | — | US | disclosed |
| US-20090280153-A1 | electrical devices, anti-scarring agents, and therapeutic compositions | ANGIOTECH INTERNATIONAL AG (CH) | 2009-11-12 | — | — | US | disclosed |
| US-20090226500-A1 | SUTURES AND ANTI-SCARRING AGENTS | ANGIOTECH PHARMACEUTICALS, INC (CA) | 2009-09-10 | — | — | US | disclosed |
| WO-2006121522-A2 | IMPLANTABLE SENSORS AND PUMPS, ANTI-SCARRING AGENTS, AND THERAPEUTIC COMPOSITIONS | ANGIOTECH INTERNATIONAL AG (CH) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006121518-A2 | ELECTRICAL DEVICES, ANTI-SCARRING AGENTS, AND THERAPEUTIC COMPOSITIONS | ANGIOTECH INTERNATIONAL AG (CH) | 2006-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077212-A1 | THERAPEUTIC USES OF SGLT2 INHIBITORS | SLC5A2, SLC5A1, PPARG | SCNN1A 1045/4885ALDH1A1 1133/4885KDM4E 3092/4885 |
| US-20120148604-A1 | TRP INHIBITORS AND USES THEREOF | TRPC4, TRPC1, TRPC3 | SCNN1A 221/4885ALDH1A1 4359/4885KDM4E 2206/4885 |
| US-20090226500-A1 | SUTURES AND ANTI-SCARRING AGENTS | COL1A1, COL2A1, COL14A1 | SCNN1A 1714/4885ALDH1A1 2866/4885KDM4E 2701/4885 |
| US-20090280153-A1 | electrical devices, anti-scarring agents, and therapeutic compositions | GAP43, TNNC1, GJB2 | SCNN1A 124/4885ALDH1A1 1855/4885KDM4E 3938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.